The second sentence the apelin receptor knows, written in a different sequence and spoken first, while the heart is still being built.
Identity
- Class
- APELA-derived peptide (mature form ~32 aa)
- Source
- Embryo; adult endothelium, kidney, and prostate
- Receptor
- Apelin receptor (APLNR / APJ)
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Elabela, also called Toddler, is encoded by APELA, a gene once annotated as non-coding. It shares little sequence with apelin and still activates the same receptor. In the embryo it is required for heart formation at a stage when apelin is dispensable for that step. In adults it can dilate vessels and support cardiac contraction, the same hemodynamic direction as apelin.
Reference notes
- Found independently in 2013 (elabela) and 2014 (Toddler) and treated by IUPHAR as a second endogenous apelin-receptor ligand.
- The precursor is cleaved to shorter active pieces, including forms of about 32, 22, and 11 residues.
- Sequence identity with apelin is low. The receptor reads a shared shape, not a shared sentence.
Regulatory status
United States · verified September 2026- Basis
- No elabela product. It is the second endogenous ligand of the apelin receptor, studied for development and cardiovascular effects, with no approved drug.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the date above is the last time this row was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Elabela (ELA)?
- The second ligand of the apelin receptor, required for early heart development. Structurally it is APELA-derived peptide (mature form ~32 aa).
- How does ELA work?
- Elabela, also called Toddler, is encoded by APELA, a gene once annotated as non-coding. It shares little sequence with apelin and still activates the same receptor. In the embryo it is required for heart formation at a stage when apelin is dispensable for that step. In adults it can dilate vessels and support cardiac contraction, the same hemodynamic direction as apelin.
- How strong is the evidence for ELA?
- PeptideHormone grades ELA at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an endogenous signal the body produces itself, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of ELA?
- The reported circulating half-life of ELA is Minutes (peptide ligand).
- Is ELA FDA-approved?
- No — as of September 2026, ELA is a native hormone with no drug product of its own, though engineered analogs may be approved. No elabela product. It is the second endogenous ligand of the apelin receptor, studied for development and cardiovascular effects, with no approved drug. Status is US-centric and can change; check the FDA record for the current position.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.ELABELA: a hormone essential for heart development signals via the apelin receptor · Developmental cell, 2013 · PMID 24316148
- 2.Toddler: an embryonic signal that promotes cell movement via Apelin receptors · Science (New York, N.Y.), 2014 · PMID 24407481